Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors

SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced results from three studies showing that treatment with Campath(R) (alemtuzumab) showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who have poor prognostic indicators. These findings were presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco, California.

Treatment for CLL can be complicated by genetic risk factors. In some cases of CLL, at least one of the 23 pairs of chromosomes in a cell is found to be either deleted or part of it is lost. One deletion that is occasionally seen in CLL patients is the loss of the short arm of chromosome 17 (17p deletion), which may indicate a poor prognosis including significantly inferior survival compared to other CLL patients. Past studies have shown that treatment naive CLL patients were less likely to have 17p deletions than previously treated patients with CLL, indicating that cytogenetic abnormalities may be acquired during the course of treatment. Effective CLL therapies for patients with 17p deletion are limited.

In one analysis of high-risk patients (abstract #3164), authors used the largest database available on the efficacy of Campath monotherapy to conduct a retrospective analysis of Campath treatment in 138 patients with advanced CLL, stratified according to cytogenetics. Of these patients, 33 percent had the 17p deleted cytogenetic abnormality. Campath administration was found to provide an overall response rate [ORR; complete response rate (CRR) + partial response rate (PRR)] of 38 percent in the total cohort, and an ORR of 44 percent in patients with 17p deletion. Additionally, in patients with 17p deletion, treatment with Campath resulted in progression free survival (PFS) and overall survival (OS) of 7.1 month
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Nov. 15, 2011 Reportlinker.com announces that ... in its catalogue: ... India & China ... emerging economies represent a combined pharmaceutical market ...
... Pa, Nov. 15, 2011 As any purchasing manager knows, ... shipping options is time lost. When purchasing surgical instruments ... In January of 2010, Robert Edelstein, President of Millennium ... Saints Charities seeking a vendor for eye surgical instruments ...
Cached Medicine Technology:The Outlook for Pharmaceuticals in Brazil, Russia, India & China 2The Outlook for Pharmaceuticals in Brazil, Russia, India & China 3The Outlook for Pharmaceuticals in Brazil, Russia, India & China 4The Outlook for Pharmaceuticals in Brazil, Russia, India & China 5Millennium Surgical Corp. Provides Instruments to Latter Day Saints Charities for Humanitarian Projects 2
(Date:7/12/2014)... “After my mom’s stroke, she loss the use ... loss the use of his left side. Eating became a difficult ... help people like them enjoy eating again,” said an inventor, from ... PATRICIA CAROL HALL PLATE (P C H PLATE). , The PATRICIA ... way to eat for individuals who suffer from stroke, experience tremors ...
(Date:7/12/2014)... With prom shopping reaching its final days, VogueQueen.com, a ... showcase its new and trendy apparels. Recently, the company ... its online shop. Additionally, it is now providing huge ... According to the company’s sales manager, the promotion will ... , He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... 2014 Utah Valley Entrepreneurial Forum Top ... awards being bestowed to companies in revenue, and pre-revenue ... community with recognition for new ideas as well as ... revenue. , 25 Under 5 highlights outstanding Utah entrepreneurs ... under 5 years old. Award recipients were recognized at ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... with highest levels are more apt to have joint replacement, ... of a certain protein strongly predict the risk of hip ... a new study shows. , The research involved 912 healthy ... led to a knee or hip replacement between 1990 and ...
... /PRNewswire/ - rL Solutions, the leading provider of healthcare ... be sponsoring the 2009 MITSS HOPE Award. MITSS and ... 8th Annual Dinner and Fundraiser on Thursday, November 12, ... MITSS established this award in 2008 to recognize people ...
... , , , ... Francisco SPCA ( www.sfspca.org ), the city,s leading privately supported, ... and safety. , , Whether traveling out of ... The SF/SPCA offers this guide for quick and easy reference: ...
... , , , , ... On Tuesday, Governor Schwarzenegger line-item vetoed the Department of Public Health,s ... domestic violence shelters and centers. , , ... advocacy, assistance with restraining orders, counseling and other vital support services. ...
... R.I., July 30 CVS/pharmacy, the nation,s largest retail pharmacy, announced ... with visual impairments and other disabilities. The Company has installed ... website in 2009. , , ... , Today,s announcement is the result of a ...
... patients (three male and seven female) with hepatic angiomyolipoma, ... 19-78 years). Of these patients, dynamic contrast CT showed ... density, absence of a capsule, and prominent central vessels ... with or without a fat component in four cases ...
Cached Medicine News:Health News:Biomarker Could Predict Severe Osteoarthritis 2Health News:rL Solutions to Sponsor 2009 MITSS HOPE Award 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 3Health News:Governor Eliminates Funding to Domestic Violence Programs 2Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 2Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 3Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 4
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... The Wet-Field Coagulator provides precise episcleral, ... peripheral tissue trauma. Controlled Rf diathermy ... comprehensive line of bipolar Eraser instruments, ... enhanced features that ensure a high ...
Medicine Products: